Skip to content
Sonic
AI
Sonic
AI
Home
Discover
Ask Sonic
Projects
Use with Claude or ChatGPT
Show me around
Request source or feature
Theravance's strategic review with Andy Summers $TBPH, Sonic AI
Home
/
Yet Another Value Podcast
/
Theravance's strategic review with Andy Summers $TBPH
Yet Another Value Podcast
Notify me
•
Mar 29, 2026
•
47:02
Interview
Theravance's strategic review with Andy Summers $TBPH
From
Yet Another Value Podcast
Andy Summers
(CIO, Summers Value, guest)
Get the full transcript next time Yet Another Value Podcast releases an episode
Summary, key quotes, top claims, and the searchable transcript — emailed automatically. No card needed.
Sign up
Executive Summary
Theravance Biopharma (TBPH) is a compelling special situation following a 30-35% stock drop after its only pipeline drug failed a Phase 3 trial, pivoting it to a single-product company.
The company's core value lies in its 35% economic interest in the growing COPD drug Upelri, co-marketed with Viatris, which has patent protection until 2039.
Driven by activist investors with board seats, TBPH has launched an accelerated strategic review, with a sale of the company or its Upelri asset to partner Viatris being the highly anticipated outcome.
The investment thesis presents an asymmetric risk/reward profile, with a protected downside (significant cash, ongoing free cash flow) and a potential 40-50% upside to a fair value of $20-$22 per share, with a deal expected before the next earnings call.
Continue your research
Keep pulling the thread on Andy Summers.
Activist-Driven Strategic Pivot
The Upelri Asset as Core Value
The Inevitable Acquirer (Viatris)
Or ask anything across 400+ expert conversations
12
quotes
Transcript
Key Arguments
Analysis
Quotes & Entities
12
Related
Loading transcript...
Processed May 4, 2026
Daily intelligence brief →
yt-dlp + mlx-whisper + Gemini